MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1

Journal of Virology

Volumn 88, Issue 16, 2014, Pages 9027-9037

  Jung, Yu Jin ^a   Choi, Hoyun ^a   Kim, Hyoji ^a   Lee, Suk Kyeong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN BRLF1; IMMEDIATE EARLY PROTEIN BZLF1; LUCIFERASE; MICRORNA; MICRORNA BAMHI A RIGHTWARD TRANSCRIPT 5P; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; BRLF1 GENE; BZLF1 GENE; CONTROLLED STUDY; EMBRYO; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; GENETIC STABILITY; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; VIRUS LATENCY; VIRUS STRAIN;

3' UNTRANSLATED REGIONS; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION; GENES, IMMEDIATE-EARLY; GENES, VIRAL; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MICRORNAS; TRANS-ACTIVATORS; VIRAL PROTEINS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84904864063     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00721-14     Document Type: Article

References (54)

1. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768. http://dx.doi.org/10.1038/nrc1452.
2. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ. 2007. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat. Res. 133:69-127. http://dx.doi.org/10.1007/978-0-387-46816-7_3.
3. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. 2007. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv. Cancer Res. 97:81-109. http://dx.doi.org/10.1016/S0065-230X(06)97004-3.
4. Boss IW, Renne R. 2011. Viral miRNAs and immune evasion. Biochim. Biophys. Acta 1809:708-714. http://dx.doi.org/10.1016/j.bbagrm.2011.06.012.
5. Cullen BR. 2009. Viral and cellular messenger RNA targets of viral microRNAs. Nature 457:421-425. http://dx.doi.org/10.1038/nature07757.
6. Cheung P, Panning B, Smiley JR. 1997. Herpes simplex virus immediateearly proteins ICP0 and ICP4 activate the endogenous human alphaglobin gene in nonerythroid cells. J. Virol. 71:1784-1793.
7. Umbach J, Kramer M, Jurak I, Karnowski H, Coen D, Cullen B. 2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454:780-783. http://dx.doi.org/10.1038/nature07103.
8. Murphy E, Vanicek J, Robins H, Shenk T, Levine AJ. 2008. Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc. Natl. Acad. Sci. U. S. A. 105:5453-5458. http://dx.doi.org/10.1073/pnas.0711910105.
9. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. 2007. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv. Cancer Res. 97:81-109. http://dx.doi.org/10.1016/S0065-230X(06)97004-3.
10. Lin X, Liang D, He Z, Deng Q, Robertson E, Lan K. 2011. miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One 6:e16224. http://dx.doi.org/10.1371/journal.pone.0016224.
11. Bellare P, Ganem D. 2009. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 6:570-575. http://dx.doi.org/10.1016/j.chom.2009.11.008.
12. Lu F, Stedman W, Yousef M, Renne R, Lieberman PM. 2010. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virusencoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J. Virol. 84:2697-2706. http://dx.doi.org/10.1128/JVI.01997-09.
13. Yan Q, Ma X, Shen C, Cao X, Feng N, Qin D, Zeng Y, Zhu J, Gao SJ, Lu C. 2014. Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA Hsa-miR-1258. J. Virol. 88:4987-5000. http://dx.doi.org/10.1128/JVI.00025-14.
14. Ragoczy T, Heston L, Miller G. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984.
15. Hardwick JM, Lieberman PM, Hayward SD. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
16. Countryman J, Miller G. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U. S. A. 82:4085-4089. http://dx.doi.org/10.1073/pnas.82.12.4085.
17. Zalani S, Holley-Guthrie E, Kenney S. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. U. S. A. 93:9194-9199. http://dx.doi.org/10.1073/pnas.93.17.9194.
18. Hsu TY, Chang Y, Wang PW, Liu MY, Chen MR, Chen JY, Tsai CH. 2005. Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. J. Gen. Virol. 86:317-322. http://dx.doi.org/10.1099/vir.0.80556-0.
19. Manet E, Gruffat H, Trescol-Biemont MC, Moreno N, Chambard P, Giot JF, Sergeant A. 1989. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8:1819-1826.
20. Kenney SC, Mertz JE. 2014. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin. Cancer Biol. 26C:60-68. http://dx.doi.org/10.1016/j.semcancer.2014.01.002.
21. Chen C, Li D, Guo N. 2009. Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors. Cancer Biol. Ther. 8:987-995. http://dx.doi.org/10.4161/cbt.8.11.8369.
22. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089. http://dx.doi.org/10.1093/emboj/19.12.3080.
23. Sinclair AJ, Brimmell M, Shanahan F, Farrell PJ. 1991. Pathways of activation of the Epstein-Barr virus productive cycle. J. Virol. 65:2237-2244.
24. Liu P, Speck SH. 2003. Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310: 199-206. http://dx.doi.org/10.1016/S0042-6822(03)00145-4.
25. Feng WH, Kraus RJ, Dickerson SJ, Lim HJ, Jones RJ, Yu X, Mertz JE, Kenney SC. 2007. ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J. Virol. 81:10113-10122. http://dx.doi.org/10.1128/JVI.00692-07.
26. Kraus RJ, Perrigoue JG, Mertz JE. 2003. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J. Virol. 77:199-207. http://dx.doi.org/10.1128/JVI.77.1.199-207.2003.
27. Yu X, Wang Z, Mertz JE. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194. http://dx.doi.org/10.1371/journal.ppat.0030194.
28. Ellis-Connell AL, Iempridee T, Xu I, Mertz JE. 2010. Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. J. Virol. 84:10329-10343. http://dx.doi.org/10.1128/JVI.00923-10.
29. Lin Z, Wang X, Fewell C, Cameron J, Yin Q, Flemington EK. 2010. Differential expression of the miR-200 family microRNAs in epithelial and B cells and regulation of Epstein-Barr virus reactivation by the miR-200 family member miR-429. J. Virol. 84:7892-7897. http://dx.doi.org/10.1128/JVI.00379-10.
30. Chen SJ, Chen GH, Chen YH, Liu CY, Chang KP, Chang YS, Chen HC. 2010. Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. PLoS One 5:e12745. http://dx.doi.org/10.1371/journal.pone.0012745.
31. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR. 2006. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2:e23. http://dx.doi.org/10.1371/journal.ppat.0020023.
32. Zhu JY, Pfuhl T, Motsch N, Barth S, Nicholls J, Grasser F, Meister G. 2009. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J. Virol. 83:3333-3341. http://dx.doi.org/10.1128/JVI.01689-08.
33. Kim do N, Chae HS, Oh ST, Kang JH, Park CH, Park WS, Takada K, Lee JM, Lee WK, Lee SK. 2007. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J. Virol. 81:1033-1036. http://dx.doi.org/10.1128/JVI.02271-06.
34. Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A, Iwakiri D, Takada K, Wiedmer A, Showe L, Lieberman P, Nishikura K. 2010. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J. Biol. Chem. 285:33358-33370. http://dx.doi.org/10.1074/jbc.M110.138362.
35. Li Z, Chen X, Li L, Liu S, Yang L, Ma X, Tang M, Bode AM, Dong Z, Sun L, Cao Y. 2012. EBV encoded miR-BHRF1-1 potentiates viral lytic replication by downregulating host p53 in nasopharyngeal carcinoma. Int. J. Biochem. Cell Biol. 44:275-279. http://dx.doi.org/10.1016/j.biocel.2011.11.007.
36. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, Jaker C, Hock J, Meister G, Grasser FA. 2008. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res. 36:666-675. http://dx.doi.org/10.1093/nar/gkm1080.
37. Oh ST, Seo JS, Moon UY, Kang KH, Shin DJ, Yoon SK, Kim WH, Park JG, Lee SK. 2004. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 320:330-336. http://dx.doi.org/10.1016/j.virol.2003.12.005.
38. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, Song SY, Kang YK, Bang YJ, Kim YH, Kim JP. 1997. Establishment and characterization of human gastric carcinoma cell lines. Int. J. Cancer 70:443-449. http://dx.doi.org/10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G.
39. Kim do N, Seo MK, Choi H, Kim SY, Shin HJ, Yoon AR, Tao Q, Rha SY, Lee SK. 2013. Characterization of naturally Epstein-Barr virusinfected gastric carcinoma cell line YCCEL1. J. Gen. Virol. 94:497-506. http://dx.doi.org/10.1099/vir.0.045237-0.
40. Borza CM, Hutt-Fletcher LM. 2002. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat. Med. 8:594-599. http://dx.doi.org/10.1038/nm0602-594.
41. Huang J, Liao G, Chen H, Wu FY, Hutt-Fletcher L, Hayward GS, Hayward SD. 2006. Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J. Virol. 80:1098-1109. http://dx.doi.org/10.1128/JVI.80.3.1098-1109.2006.
42. Tsurumi T, Kobayashi A, Tamai K, Daikoku T, Kurachi R, Nishiyama Y. 1993. Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit. J. Virol. 67:4651-4658.
43. Chou SP, Tsai CH, Li LY, Liu MY, Chen JY. 2004. Characterization of monoclonal antibody to the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2. Hybrid. Hybridomics 23:29-37. http://dx.doi.org/10.1089/153685904322772006.
44. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. 2010. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70:5518-5527. http://dx.doi.org/10.1158/0008-5472.CAN-10-0646.
45. Chang PJ, Liu ST. 2001. Function of the intercistronic region of BRLF1-BZLF1 bicistronicmRNAin translating the Zta protein of Epstein-Barr virus. J. Virol. 75:1142-1151. http://dx.doi.org/10.1128/JVI.75.3.1142-1151.2001.
46. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. 2010. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063. http://dx.doi.org/10.1371/journal.ppat.1001063.
47. Shin HJ, Kim do N, Lee SK. 2011. Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma. Mol. Cells 32:173-179. http://dx.doi.org/10.1007/s10059-011-0066-y.
48. Seo JS, Kim TG, Hong YS, Chen JY, Lee SK. 2011. Contribution of Epstein-Barr virus infection to chemoresistance of gastric carcinoma cells to 5-fluorouracil. Arch. Pharm. Res. 34:635-643. http://dx.doi.org/10.1007/s12272-011-0414-7.
49. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M. 2010. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 70:4719-4727. http://dx.doi.org/10.1158/0008-5472.CAN-09-4620.
50. Marquitz AR, Mathur A, Chugh PE, Dittmer DP, Raab-Traub N. 2014. Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J. Virol. 88:1389-1393. http://dx.doi.org/10.1128/JVI.02662-13.
51. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, Middeldorp J, Shapiro M, Thorley-Lawson DA. 2011. A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog. 7:e1002193. http://dx.doi.org/10.1371/journal.ppat.1002193.
52. Young DF, Carlos TS, Hagmaier K, Fan L, Randall RE. 2007. AGS and other tissue culture cells can unknowingly be persistently infected with PIV5; a virus that blocks interferon signalling by degrading STAT1. Virology 365:238-240. http://dx.doi.org/10.1016/j.virol.2007.03.061.
53. Lin TC, Liu TY, Hsu SM, Lin CW. 2013. Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet translation with secondary suppression of p53 in invasive nasal NK/T-cell lymphoma. Am. J. Pathol. 182:1865-1875. http://dx.doi.org/10.1016/j.ajpath.2013.01.025.
54. Huang WT, Lin CW. 2014. EBV-encoded miR-BART20-5p and miRBART8 inhibit the IFN-gamma-STAT1 pathway associated with disease progression in nasal NK-cell lymphoma. Am. J. Pathol. 184:1185-1197. http://dx.doi.org/10.1016/j.ajpath.2013.12.024.